Key result
Intracoronary chloroquine terminates cardiac arrhythmias in isolated hearts by blocking inward rectifier potassium channels.
Why the study?
Up-regulation of inward rectifier potassium channels can perpetuate atrial and ventricular tachyarrhythmias, and targeting their cytoplasmic domains may provide effective antifibrillatory therapy.
Does chloroquine reduce fibrillatory frequency and terminate arrhythmias in isolated mammalian hearts?
Does chloroquine reduce fibrillatory frequency and terminate arrhythmias in isolated mammalian hearts?
Chloroquine exerts potent antiarrhythmic effects by blocking inward rectifier potassium channels via interaction with specific residues in their cytoplasmic domains, identifying a novel target for antifibrillatory drug development.
Atrial and ventricular tachyarrhythmias can be perpetuated by up‐regulation of inward rectifier potassium channels. Thus, it may be beneficial to block inward rectifier channels under conditions in which their function becomes arrhythmogenic ( e.g ., inherited gain‐of‐function mutation channelopathies, ischemia, and chronic and vagally mediated atrial fibrillation). We hypothesize that the antimalarial quinoline chloroquine exerts potent antiarrhythmic effects by interacting with the cytoplasmic domains of Kir2.1 ( I K1 ), Kir3.1 ( I KACh ), or Kir6.2 ( I KATP ) and reducing inward rectifier potassium currents. In isolated hearts of three different mammalian species, intracoronary chloroquine perfusion reduced fibrillatory frequency (atrial or ventricular), and effectively terminated the arrhythmia with resumption of sinus rhythm. In patch‐clamp experiments chloroquine blocked I K1 , I KACh , and I KATP . Comparative molecular modeling and ligand docking of chloroquine in the intracellular domains of Kir2.1, Kir3.1, and Kir6.2 suggested that chloroquine blocks or reduces potassium flow by interacting with negatively charged amino acids facing the ion permeation vestibule of the channel in question. These results open a novel path toward discovering antiarrhythmic pharmacophores that target specific residues of the cytoplasmic domain of inward rectifier potassium channels.—Noujaim, S. F., Stuckey, J. A., Ponce‐Balbuena, D., Ferrer‐Villada, T., López‐Izquierdo, A., Pandit, S., Calvo, C. J., Grzeda, K. R., Berenfeld, O., Sánchez Chapula, J. A., Jalife, J. Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets. FASEB J . 24, 4302–4312 (2010). www.fasebj.org
No takes yet. Share an insight, caveat, or question.
Noujaim et al. (2010) studied Atrial and ventricular tachyarrhythmias. Chloroquine was evaluated on Fibrillatory frequency and arrhythmia termination. Intracoronary chloroquine perfusion reduced fibrillatory frequency and effectively terminated arrhythmias in isolated mammalian hearts by blocking inward rectifier potassium channels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: